1.22
price down icon2.66%   -0.04
 
loading
Schlusskurs vom Vortag:
$1.26
Offen:
$1.25
24-Stunden-Volumen:
56,942
Relative Volume:
0.22
Marktkapitalisierung:
$22.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.29M
KGV:
-1.7429
EPS:
-0.7
Netto-Cashflow:
$-6.47M
1W Leistung:
-3.43%
1M Leistung:
-19.84%
6M Leistung:
-26.11%
1J Leistung:
-11.12%
1-Tages-Spanne:
Value
$1.21
$1.27
1-Wochen-Bereich:
Value
$1.16
$1.29
52-Wochen-Spanne:
Value
$0.94
$2.2299

NanoViricides Inc Stock (NNVC) Company Profile

Name
Firmenname
NanoViricides Inc
Name
Telefon
203-937-6137
Name
Adresse
1 Controls Drive, Shelton, CT
Name
Mitarbeiter
7
Name
Twitter
@nnvcnyse
Name
Nächster Verdiensttermin
2025-09-03
Name
Neueste SEC-Einreichungen
Name
NNVC's Discussions on Twitter

Vergleichen Sie NNVC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NNVC
NanoViricides Inc
1.227 22.68M 0 -8.29M -6.47M -0.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
432.20 109.65B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.25 82.46B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.68 58.81B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
909.10 56.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
207.34 43.62B 447.02M -1.18B -906.14M -6.1812

NanoViricides Inc Stock (NNVC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2015-02-11 Eingeleitet Midtown Partners Strong Buy

NanoViricides Inc Aktie (NNVC) Neueste Nachrichten

pulisher
06:32 AM

What drives NanoViricides Inc stock priceAnalyst Downgrades & Free Superior Stock Performance - earlytimes.in

06:32 AM
pulisher
Nov 27, 2025

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - St. Cloud Times

Nov 27, 2025
pulisher
Nov 26, 2025

NanoViricides Holds 2025 Annual Stockholders Meeting - TipRanks

Nov 26, 2025
pulisher
Nov 26, 2025

NanoViricides Dual Track Clinical Strategy Explained by a Research ReportBroad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - Livingston Daily

Nov 26, 2025
pulisher
Nov 26, 2025

NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Marion Star

Nov 26, 2025
pulisher
Nov 25, 2025

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value - Canton Daily Ledger

Nov 25, 2025
pulisher
Nov 24, 2025

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Bluffton Today

Nov 24, 2025
pulisher
Nov 23, 2025

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - York Daily Record

Nov 23, 2025
pulisher
Nov 21, 2025

Why NanoViricides Inc. (NV3P) stock stays resilient2025 Stock Rankings & Precise Swing Trade Entry Alerts - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Why NanoViricides Inc. stock stays resilientPortfolio Value Report & Technical Confirmation Trade Alerts - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Will NanoViricides Inc. stock recover faster than industryJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Why NanoViricides Inc. stock is trending on social media2025 Market Overview & Safe Entry Point Identification - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Will NanoViricides Inc. stock continue upward momentumJuly 2025 PreEarnings & Free Fast Entry Momentum Trade Alerts - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Can NanoViricides Inc. (NV3P) stock ride next bull market cycleWeekly Trade Analysis & Weekly High Conviction Ideas - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Is NanoViricides Inc. (NV3P) stock supported by free cash flow2025 Market Outlook & Growth Focused Investment Plans - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - Erie Times-News

Nov 20, 2025
pulisher
Nov 20, 2025

Will NanoViricides Inc. stock sustain bullish trend into 20252025 Year in Review & Technical Confirmation Trade Alerts - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Is NanoViricides Inc. (NV3P) stock a good hedge against inflationTrade Volume Report & Weekly Setup with ROI Potential - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Will NanoViricides Inc. stock boost dividends furtherMarket Risk Summary & Community Consensus Picks - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Is NanoViricides Inc. stock a buy before product launchesJuly 2025 Trends & Free Real-Time Market Sentiment Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Published on: 2025-11-19 20:46:00 - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Why institutional investors increase stakes in NanoViricides Inc. (NV3P) stockEarnings Risk Report & Risk Controlled Swing Trade Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

How NanoViricides Inc. stock trades after earnings2025 Year in Review & Expert-Curated Trade Recommendations - newser.com

Nov 19, 2025

Finanzdaten der NanoViricides Inc-Aktie (NNVC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$39.77
price down icon 0.30%
$104.72
price down icon 0.89%
$32.19
price up icon 0.74%
$103.58
price up icon 0.79%
biotechnology ONC
$342.08
price up icon 0.25%
$207.41
price up icon 1.52%
Kapitalisierung:     |  Volumen (24h):